99 studies found for:    "beta thalassemia"
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Completed Hydroxyurea to Treat Beta-Thalassemia (Cooley's Anemia)
Conditions: Beta Thalassemia;   Hemoglobinopathy
Intervention: Drug: Hydroxyurea
2 Completed Phase 1/2 Study of HQK-1001 in Patients With Beta Thalassemia
Condition: Beta Thalassemia
Interventions: Drug: HQK-1001;   Drug: Placebo
3 Unknown  Beta-thalassemia and Microparticles
Conditions: Thalassemia Major (TM);   Thalassemia Intermedia (TI);   Microparticles (MP)Originating From Platelets, Endothelial Cells and Monocytes
Intervention: Other: Physiopathology
4 Completed Trial of HQK-1001 in Beta Thalassemia Intermedia in Lebanon
Condition: Beta Thalassemia Intermedia
Intervention: Drug: Sodium 2,2 dimethylbutyrate
5 Recruiting Study to Determine the Safety and Tolerability of Sotatercept (ACE-011) in Adults With Beta( β)- Thalassemia.
Conditions: Beta Thalassemia Major;   Beta Thalassemia Intermedia
Interventions: Drug: Dose level 1a;   Drug: Dose level 1b;   Drug: Dose level 2;   Drug: dose level 3;   Drug: dose level 4;   Drug: dose level 5
6 Not yet recruiting An Algorithm to Start Iron Chelation in Minimally Transfused Young Beta-thalassemia Major Patients
Condition: Beta Thalassemia Major
Intervention: Drug: Deferiprone
7 Completed Efficacy Study of the Use of Sequential DFP-DFO Versus DFP
Conditions: Beta-Thalassemia;   Thalassemia Major
Interventions: Drug: Deferiprone (DFP) and Deferoxamine (DFO);   Drug: Deferiprone (DFP)
8 Unknown  Genetic Factors Affecting the Severity of Beta Thalassemia
Condition: Beta Thalassemia
Intervention:
9 Completed Evaluating the Safety of G-CSF Mobilization in Individuals With Beta Thalassemia Major
Condition: Beta-Thalassemia
Intervention: Drug: Hydroxyurea
10 Completed Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand
Condition: Beta Thalassemia Intermedia
Intervention: Drug: sodium 2,2 dimethylbutyrate
11 Completed Iron Balance Study of DFO and GT56-252 in Patients With Transfusional Iron Overload Secondary to Beta-Thalassemia
Condition: Beta-Thalassemia
Interventions: Drug: Deferitrin (GT56-252);   Drug: desferoxamine (DFO)
12 Completed Efficacy and Safety of Neridronate (Nerixia®)to Treat Osteoporosis in Patients With TM and TI
Conditions: Osteoporosis;   Thalassemia Major;   Thalassemia Intermedia
Intervention: Drug: Neridronate
13 Recruiting Evaluating the Safety and Effectiveness of Mozobil Mobilization in Adults With Beta-Thalassemia Major
Condition: Beta-Thalassemia
Intervention: Drug: Mozobil
14 Completed Cardiac T2* in Beta-thalassemia Patients on Deferasirox Treatment
Conditions: Beta-thalassemia;   Iron Overload
Intervention: Drug: Deferasirox
15 Completed Evaluating the Efficacy of Deferasirox in Transfusion Dependent Chronic Anaemias (Myelodysplastic Syndrome, Beta-thalassaemia Patients) With Chronic Iron Overload
Conditions: Myelodysplastic Syndromes;   Beta-Thalassemia
Intervention: Drug: deferasirox
16 Completed A Study of Long-term Treatment With Deferasirox in Patients With Beta-thalassemia and Transfusional Hemosiderosis
Conditions: Beta-Thalassemia;   Hemosiderosis
Intervention: Drug: deferasirox
17 Completed Assess the Feasibility and Safety of Granulocyte Colony Stimulating Factor (GCSF) Mobilization of CD34+ Hematopoietic Progenitor Cells in Patients With Betathalassemia Major
Conditions: Beta Thalassemia Major;   Congenital Anemias
Intervention: Genetic: GCSF, Central venous line placement, Stem cell Collection (leukapheresis)
18 Unknown  Combined Chelation Treatment With Deferiprone and Deferoxamine in Thalassemia Major
Condition: Beta-Thalassemia
Intervention: Drug: deferiprone
19 Completed
Has Results
Extension Study of the Efficacy and Safety of Deferasirox Treatment in Beta-thalassemia Patients With Transfusional Hemosiderosis (Study Amended to 2-year Duration)
Conditions: Beta-thalassemia Major;   Hemosiderosis;   Iron Overload;   Rare Anemia
Intervention: Drug: Deferasirox
20 Recruiting A Study Evaluating the Safety and Efficacy of the LentiGlobin® BB305 Drug Product in Beta-Thalassemia Major Subjects
Condition: Beta-thalassemia Major
Intervention: Genetic: LentiGlobin® BB305 Drug Product

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years